Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S236800, C514S424000, C548S229000
Reexamination Certificate
active
07998992
ABSTRACT:
Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor.A compound represented by the formula:its pharmaceutically acceptable salt, or a solvate thereof,wherein R1is optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle or optionally substituted heterocyclealkyl,X is —O—, —NR3—, —NR3C(═O)— or —NR3S(═O)2—,R2is optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl,R3is hydrogen or optionally substituted alkyl.
REFERENCES:
patent: 3062828 (1962-11-01), Lunsford
patent: 4066628 (1978-01-01), Ashida et al.
patent: 4146638 (1979-03-01), Renth et al.
patent: 4602093 (1986-07-01), Baldwin et al.
patent: 4806655 (1989-02-01), Wagnon et al.
patent: 5480899 (1996-01-01), Yano et al.
patent: 5488064 (1996-01-01), Sher
patent: 5521202 (1996-05-01), Yano et al.
patent: 5606069 (1997-02-01), Epstein et al.
patent: 5827857 (1998-10-01), Riedl et al.
patent: 5843975 (1998-12-01), Jegham et al.
patent: 2004/0242660 (2004-12-01), Straub et al.
patent: 2008/0306070 (2008-12-01), Perzborn et al.
patent: 2109651 (1971-09-01), None
patent: 0153682 (1982-01-01), None
patent: 0064294 (1982-11-01), None
patent: 0251938 (1991-11-01), None
patent: 0645387 (1995-03-01), None
patent: 0605729 (2000-07-01), None
patent: 1261606 (2002-12-01), None
patent: 1526132 (2005-04-01), None
patent: 1251128 (2006-12-01), None
patent: 1852425 (2007-11-01), None
patent: 1864971 (2007-12-01), None
patent: 1894919 (2008-03-01), None
patent: 1953145 (2008-08-01), None
patent: 2006286 (2008-12-01), None
patent: 938424 (1963-10-01), None
patent: 49-20768 (1974-05-01), None
patent: 05-148247 (1993-06-01), None
patent: 11-035534 (1999-02-01), None
patent: 2000-136186 (2000-05-01), None
patent: 2000-290265 (2000-10-01), None
patent: 2001-055383 (2001-02-01), None
patent: 99/03846 (1999-01-01), None
patent: 99/64417 (1999-12-01), None
patent: 02/072542 (2002-09-01), None
patent: 2004/069244 (2004-08-01), None
patent: 2004/069832 (2004-08-01), None
patent: 2005/108360 (2005-11-01), None
patent: 2005/108361 (2005-11-01), None
patent: 2006/124490 (2006-11-01), None
patent: 2007/118185 (2007-10-01), None
Chapman et al. Neurochem. Res. 2008, vol. 33, pp. 624-636.
Vippagunta et al. Advanced Drug Delivery Reviews. 2001, vol. 28, pp. 3-26.
Tomkin et al. Proceedings of the Nutrition Society, 1991, vol. 50, pp. 583-589.
Stewart, “11 β-Hydroxysteroid dehydrogenase: implications for clinical medicine”, Clinical Molecular Endocrinology, 1996, pp. 493-499.
Kotelevtsev et al., “11 β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress”, Proc. Natl. Acad. Sci. USA, vol. 94, Dec. 1997, pp. 14924-14929.
Walker et al., “Carbenoxolone Increases Hepatic Insulin Sensitivity in Man: A Novel Role for 11-Oxosteroid Reductase in Enhancing Glucocorticoid Receptor Activation”, Journal of Clinical Endocrinology and Metabolism, vol. 80, No. 11, 1995, pp. 3155-3159.
Bujalska et al., “Does central obesity reflect ‘Cushing's disease of the omentum’?”, The Lancet, vol. 349, Apr. 26, 1997, pp. 1210-1213.
Ohno et al., “Synthesis and Structure-Activity Relationship of 4-Substituted Benzoic Acids and their Inhibitory Effect on the Biosynthesis of Fatty Acids and Sterols”, Arc. Pharm. Chem. Life Sci., vol. 338, 2005, pp. 147-158.
Rastogi et al.. “Solid phase synthesis of 3,5-disubstituted oxazolidin-2-ones”, Tetrahedron Letters 43, 2002, pp. 8327-8330.
Maier et al., “Efficient high-performance liquid chromatographic enantioseparation of five-membered aryl-substituted lactones and cyclic carbamates on a (R,R)-diaminodihydroethanoanthracene-derived chiral stationary phase,” Journal of Chromatography A, vol. 740, 1996, pp. 11-19.
{hacek over (Z)}ilić et al., “Studies in the Formation of Poly(oxazolidone)s. III. Catalysis and Kinetics of the Model Oxazolidone Formation from Cyclohexyl Isocyanate and Phenylglycidyl Ether”, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 27, 1989, pp. 1843-1851.
Cardillo et al., “An Efficient Synthesis of (R)-(+)- and (S)-(−)-Propranolol from Resolved 5-Iodomethyloxazolidin-2-ones”, Tetrahedron, vol. 43, No. 11, 1987 pp. 2505-2512.
Baldwin et al., “β1-Selective Adrenoceptor Antagonists: Examples of the 2-[4-[3-(Substituted amino)-2-hydroxypropoxy]phenyl]imidazole Class. 2”, Journal of Medicinal Chemistry, vol. 29, No. 6, 1986, pp. 1065-1080.
Kordomenos et al., “Oxazolidone Coatings Part 1: Synthesis and Structure”, Journal of Coatings Technology, vol. 55, No. 700, May 1983, pp. 49-57.
Kordomenos et al., “Thermal Stability of Isocyanate-Based Polymers. 1. Kinetics of the Thermal Dissociation of Urethane, Oxazolidone, and Isocyanurate Groups”, Macromolecules, vol. 14, No. 5, 1981, pp. 1434-1437.
Gulbins et al., “Synthese von substituierten Oxazolidonen-(2)”, Chemische Berichte, Jahrg. 93, 1960, pp. 1975-1982.
Lunsford et al., “5-Aryloxymethy1-2-oxazolidinones”, Journal of the American Chemical Society, vol. 82, Mar. 5, 1960, pp. 1166-1171.
Yeh et al., “Discovery of orally active butyrolactam 11β-HSD1 inhibitors”, Bioorganic & Medicinal Chemistry Letters 16, 2006, pp. 5555-5560.
Mai et al., “Synthesis and biochemical evaluation of (R)-5-acyloxymethyl- and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones as new anti-monoamine oxidase (anti-MAO) agents,” ARKIVOC, 2004, pp. 32-43.
Pazdro et al., “N-Mannich Bases of Some 5-Aryloxymethyl-2-oxazolidones”, Dissertationes Pharmaceuticae et Pharmacologicae, 1970, pp. 297-303.
Landini et al., “S,S-Dimethyl Dithiocarbonate as a Valuable Starting Material for the Synthesis of 5-Substituted Oxazolidinones Under Solid-Liquid Phase Transfer Catalysis (SL-PTC) Conditions”, Letters in Organic Chemistry, vol. 3, No. 11, 2006, pp. 836-841.
Anumula et al., “Synthesis of new oxazolidinonyl/oxazolidinyl carbazole derivatives for β-blocking activity,” Heterocyclic Communications, 2007, vol. 13, No. 5, pp. 315-322.
Fukasawa Hiroshi
Itai Akiko
Muto Susumu
Tokuyama Ryuko
Yanase Takeshi
Hamre Schumann Mueller & Larson P.C.
Institute of Medicinal Molecular Design Inc.
Jean-Louis Samira
Padmanabhan Sreeni
Shionogi & Co. Ltd.
LandOfFree
Oxazolidinone derivative having inhibitory activity on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazolidinone derivative having inhibitory activity on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolidinone derivative having inhibitory activity on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739123